Solid-phase Synthesis of Folate-Chlorin Conjugates for Selective Photodynamic Therapy and the Effect of Linker Variation

被引：1

作者：

Lee, Seon-Min ^{[1
]}

Ahn, Young-Deok ^{[1
]}

Mun, Hyoyoung ^{[1
]}

Goh, Byoungsook ^{[1
]}

Kim, Tae-Young ^{[1
,2
]}

Seo, Jiwon ^{[1
]}

Kim, Min-Gon ^{[1
,3
]}

机构：

[1] Sch Phys & Chem, Dept Chem, Gwangju 500712, South Korea

[2] Gwangju Inst Sci & Technol, Sch Earch Sci & Engn, Gwangju 500712, South Korea

[3] Adv Photon Res Inst, Gwangju 500712, South Korea

来源：

BULLETIN OF THE KOREAN CHEMICAL SOCIETY | 2016年 / 37卷 / 12期

基金：

新加坡国家研究基金会;

关键词：

Photodynamic therapy; Chlorin; 2-[1-Hexyloxyethyl]-2-devinyl pyropheophorbide-a; Folic acid; Linker; TARGETED DELIVERY; PHOTOSENSITIZERS; DESIGN; HPPH; PEPTOIDS; PEPTIDE; DRUG;

D O I：

10.1002/bkcs.11028

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Here, we evaluated the effect of linkers conjugating a chlorin-based photosensitizer, 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH), and folic acid to target cancer cells. Folate-HPPH conjugates with peptide, polyethylene glycol (PEG), peptoid, or 7-aminoheptanoic acid (AHA) linkers were synthesized on a solid-phase and evaluated for photodynamic therapy (PDT) efficacy. Compared to free HPPH, the folate-linker-HPPHs were effectively internalized into tumor cells and exhibited superior PDT effect upon irradiation. Tumor-targeting PDT efficacy was influenced by linker variation, with in vitro photocytotoxicities of peptide>PEG>AHA>peptoid, paralleling water solubility of the linkers. Thus, linker choice significantly affects targeted PDT efficacy providing useful information for linker design.

引用

页码：2036 / 2040

页数：5

共 39 条

[1] Monoclonal antibody therapy of cancer [J].

Adams, GP ;

Weiner, LM .

NATURE BIOTECHNOLOGY, 2005, 23 (09) :1147-1157

[2] Photosensitizers in clinical PDT [J].

Allison, Ron R. ;

Downie, Gordon H. ;

Cuenca, Rosa ;

Hu, Xin-Hua ;

Childs, Carter J. H. ;

Sibata, Claudio H. .

PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2004, 1 (01) :27-42

[3] New method for delivering a hydrophobic drug for photodynamic therapy using pure nanocrystal form of the drug [J].

Baba, Koichi ;

Pudavar, Haridas E. ;

Roy, Indrajit ;

Ohulchanskyy, Tymish Y. ;

Chen, Yihui ;

Pandey, Ravindra K. ;

Prasad, Paras N. .

MOLECULAR PHARMACEUTICS, 2007, 4 (02) :289-297

[4] Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy [J].

Bellnier, DA ;

Greco, WR ;

Nava, H ;

Loewen, GM ;

Oseroff, AR ;

Dougherty, TJ .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (01) :40-45

[5] Porphyrin-related photosensitizers for cancer imaging and therapeutic applications [J].

Berg, K ;

Selbo, PK ;

Weyergang, A ;

Dietze, A ;

Prasmickaite, L ;

Bonsted, A ;

Engesaeter, BO ;

Angell-Petersen, E ;

Warloe, T ;

Frandsen, N ;

Hogset, A .

JOURNAL OF MICROSCOPY, 2005, 218 :133-147

[6] Design and photophysical properties of new RGD targeted tetraphenylchlorins and porphyrins [J].

Boisbrun, Michel ;

Vanderesse, Regis ;

Engrand, Philippe ;

Olie, Alexis ;

Hupont, Sebastien ;

Regnouf-de-Vains, Jean-Bernard ;

Frochot, Celine .

TETRAHEDRON, 2008, 64 (16) :3494-3504

[7] The present and future role of photodynamic therapy in cancer treatment [J].

Brown, SB ;

Brown, EA ;

Walker, I .

LANCET ONCOLOGY, 2004, 5 (08) :497-508

[8] Targeted photodynamic therapy - a promising strategy of tumor treatment [J].

Bugaj, Andrzej M. .

PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES, 2011, 10 (07) :1097-1109

[9] Photodynamic therapy for cancer [J].

Dolmans, DEJGJ ;

Fukumura, D ;

Jain, RK .

NATURE REVIEWS CANCER, 2003, 3 (05) :380-387

[10] CUTANEOUS PHOTOTOXIC OCCURRENCES IN PATIENTS RECEIVING PHOTOFRIN [J].

DOUGHERTY, TJ ;

COOPER, MT ;

MANG, TS .

LASERS IN SURGERY AND MEDICINE, 1990, 10 (05) :485-488

← 1 2 3 4 →